Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
(e.g., Redesign Health, PE firms doing roll-ups) Operators make GLP-1 care scalable and profitable, bridging the gap between science and patient experience
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies
As the arsenal of incretin therapies targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors continues to expand, clinicians need to balance the myriad clinical benefits with potentially severe adverse effects (AEs) to put this principle into practice
& Mudd, S
Canonical Wnt/beta-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance
The cryo-EM map for the oxyntomodulin-bound complex enabled robust modelling and confident assignment of most of the side-chain rotamers for oxyntomodulin, the G protein and the receptor TMD (Supplementary Fig
